Syndax Pharmaceuticals Stock Performance
| SNDX Stock | USD 9.67 0.42 4.54% |
The entity has a beta of -1.31, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Syndax Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, Syndax Pharmaceuticals is expected to outperform it. At this point, Syndax Pharmaceuticals has a negative expected return of -0.21%. Please make sure to validate Syndax Pharmaceuticals' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Syndax Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Syndax Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in August 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (2.17) | Five Day Return (1.15) | Year To Date Return (32.81) | Ten Year Return (21.17) | All Time Return (21.17) |
1 | SNDX Syndax Reveals Significant Phase 2 Trial Results for Revumenib SNDX Stock News | 05/07/2025 |
2 | Balyasny Asset Management L.P. Sells 297,591 Shares of Syndax Pharmaceuticals, Inc. | 05/15/2025 |
3 | Acquisition by Botwood Nicholas A.j. of 11765 shares of Syndax Pharmaceuticals at 8.995 subject to Rule 16b-3 | 05/16/2025 |
4 | Long Term Trading Analysis for - news.stocktradersdaily.com | 06/04/2025 |
5 | Syndax Presents New Revuforj Data in RelapsedRefractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025 | 06/12/2025 |
6 | Syndax Announces FDA Priority Review of sNDA for Revuforj revu | 06/24/2025 |
7 | Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 SNDX ... | 07/02/2025 |
8 | Syndaxs Revuforj Granted FDA Priority Review for RelapsedRefractory Mutant NPM1 AML | 07/09/2025 |
9 | Syndax initiated with bullish view at Goldman Sachs, heres why SNDX | 07/10/2025 |
10 | Syndax price target lowered by 2 at UBS, heres why SNDX | 07/15/2025 |
11 | Disposition of 7534 shares by Metzger Michael A of Syndax Pharmaceuticals at 9.285 subject to Rule 16b-3 | 07/16/2025 |
| Begin Period Cash Flow | 295.6 M | |
| Total Cashflows From Investing Activities | -219.8 M |
Syndax Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,193 in Syndax Pharmaceuticals on April 20, 2025 and sell it today you would lose (226.00) from holding Syndax Pharmaceuticals or give up 18.94% of portfolio value over 90 days. Syndax Pharmaceuticals is currently does not generate positive expected returns and assumes 5.0037% risk (volatility on return distribution) over the 90 days horizon. In different words, 44% of stocks are less volatile than Syndax, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Syndax Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Syndax Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Syndax Pharmaceuticals, and traders can use it to determine the average amount a Syndax Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0419
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SNDX |
Estimated Market Risk
| 5.0 actual daily | 44 56% of assets are more volatile |
Expected Return
| -0.21 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Syndax Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Syndax Pharmaceuticals by adding Syndax Pharmaceuticals to a well-diversified portfolio.
Syndax Pharmaceuticals Fundamentals Growth
Syndax Stock prices reflect investors' perceptions of the future prospects and financial health of Syndax Pharmaceuticals, and Syndax Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Syndax Stock performance.
| Return On Equity | -0.94 | ||||
| Return On Asset | -0.36 | ||||
| Operating Margin | (4.17) % | ||||
| Current Valuation | 299.53 M | ||||
| Shares Outstanding | 86.05 M | ||||
| Price To Earning | 126.11 X | ||||
| Price To Book | 3.79 X | ||||
| Price To Sales | 18.62 X | ||||
| Revenue | 23.68 M | ||||
| Gross Profit | (199.64 M) | ||||
| EBITDA | (313.82 M) | ||||
| Net Income | (318.76 M) | ||||
| Cash And Equivalents | 350.71 M | ||||
| Cash Per Share | 5.82 X | ||||
| Total Debt | 345.74 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 17.19 X | ||||
| Book Value Per Share | 2.50 X | ||||
| Cash Flow From Operations | (274.9 M) | ||||
| Earnings Per Share | (3.85) X | ||||
| Market Capitalization | 814.01 M | ||||
| Total Asset | 724.82 M | ||||
| Retained Earnings | (1.22 B) | ||||
| Working Capital | 499.51 M | ||||
| Current Asset | 79.72 M | ||||
| Current Liabilities | 13.32 M | ||||
About Syndax Pharmaceuticals Performance
Evaluating Syndax Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Syndax Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Syndax Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 185.99 | 176.69 | |
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.55) | (0.57) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (1.11) | (1.05) |
Things to note about Syndax Pharmaceuticals performance evaluation
Checking the ongoing alerts about Syndax Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Syndax Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Syndax Pharmaceuticals generated a negative expected return over the last 90 days | |
| Syndax Pharmaceuticals has high historical volatility and very poor performance | |
| Syndax Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 23.68 M. Net Loss for the year was (318.76 M) with loss before overhead, payroll, taxes, and interest of (199.64 M). | |
| Syndax Pharmaceuticals currently holds about 350.71 M in cash with (274.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.82. | |
| Syndax Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from thefly.com: Syndax price target lowered by 2 at UBS, heres why SNDX |
- Analyzing Syndax Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Syndax Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Syndax Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Syndax Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Syndax Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Syndax Pharmaceuticals' stock. These opinions can provide insight into Syndax Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.